REVIEW Cilnidipine is a dihydropyridine dual-type calcium channel blocker. It blocks L-type voltage-gated calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals that supply blood vessels.
Hirose, Takeshi; Suzuki, Hidehiko Cilnidipine for treatment of heart diseases Jpn. Kokai Tokkyo Koho (2000), JP 2000309535 A 20001107.
L?hn M, Muzzulini U, Essin K, Tsang SY, Kirsch T, Litteral J, Waldron P, Conrad H, Klugbauer N, Hofmann F, Haller H, Luft FC, Huang Y, Gollasch M Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C. J Hypertens. 2002 May;20(5):885-93.
Yamamoto Takashi; Niwa Seiji; Ohno Seiji; Onishi Tomoyuki; Matsueda Hiroyuki; Koganei Hajime; Uneyama Hisayuki; Fujita Shin-ichi; Takeda Tomoko; Kito Morikazu; et al Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels Bioorganic & medicinal chemistry letters (2006), 16(4), 798-802.
Fukumoto S, Ishimura E, Motoyama K, Morioka T, Kimoto E, Wakikawa K, Shoji S, Koyama H, Shoji T, Emoto M, Nishizawa Y, Inaba M; Cilnidipine vs L-type calcium channel blockers Evaluation of Antihypertensive Renoprotective Effects in Diabetic patients (CLEARED) Study Investigators (2012). Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria. Diabetes Res Clin Pract. 97(1):91-8. PMID 22336632.
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. CATEGORIES APIs and Bioactives > Calcium Channel Blockers